BACKGROUND: Procalcitonin (PCT) is considered a sensitive and specific diagnostic and prognostic marker of systemic bacterial infection, but its value is questionable in certain clinical conditions, particularly in hemato-oncological patients. MATERIALS AND METHODS: We analyzed PCT and C-reactive protein (CRP) levels in 56 patients of a pediatric hematology-oncology unit during 110 consecutive non-infectious febrile episodes related to administration of T-cell antibodies (group A; n = 22), alemtuzumab (monoclonal CD52 antibody, CAMPATH-1H/group B; n = 8), interleukin-2 (IL-2/group C; n = 41), prophylactic donor granulocyte transfusions (group D; n = 9), or to acute graft-versus-host disease (aGvHD/group E; n = 10) and compared the results with 20 episodes of Gram-negative sepsis (group F). MAIN RESULTS: In the majority of the non-infectious episodes PCT and CRP increased to serum levels statistically indistinguishable from Gram-negative sepsis. Median peak levels of PCT (normal < 0.5 ng/ml)/CRP (normal < 8 mg/l) for groups A-F were 4.34/59.0 (A), 10.14/93.5 (B), 1.11/175.0 (C), 1.43/164 (D), 0.96/34.0 (E), and 8.14 ng/ml /126.0 mg/l (F). Highest single levels were observed in groups A and F. CONCLUSIONS: PCT and CRP are of limited value as diagnostic markers of sepsis during T-cell-directed immunomodulatory treatment, granulocyte support, or acute GvHD.
BACKGROUND: Procalcitonin (PCT) is considered a sensitive and specific diagnostic and prognostic marker of systemic bacterial infection, but its value is questionable in certain clinical conditions, particularly in hemato-oncological patients. MATERIALS AND METHODS: We analyzed PCT and C-reactive protein (CRP) levels in 56 patients of a pediatric hematology-oncology unit during 110 consecutive non-infectious febrile episodes related to administration of T-cell antibodies (group A; n = 22), alemtuzumab (monoclonal CD52 antibody, CAMPATH-1H/group B; n = 8), interleukin-2 (IL-2/group C; n = 41), prophylactic donor granulocyte transfusions (group D; n = 9), or to acute graft-versus-host disease (aGvHD/group E; n = 10) and compared the results with 20 episodes of Gram-negative sepsis (group F). MAIN RESULTS: In the majority of the non-infectious episodes PCT and CRP increased to serum levels statistically indistinguishable from Gram-negative sepsis. Median peak levels of PCT (normal < 0.5 ng/ml)/CRP (normal < 8 mg/l) for groups A-F were 4.34/59.0 (A), 10.14/93.5 (B), 1.11/175.0 (C), 1.43/164 (D), 0.96/34.0 (E), and 8.14 ng/ml /126.0 mg/l (F). Highest single levels were observed in groups A and F. CONCLUSIONS: PCT and CRP are of limited value as diagnostic markers of sepsis during T-cell-directed immunomodulatory treatment, granulocyte support, or acute GvHD.
Authors: Mirjam Christ-Crain; Daiana Jaccard-Stolz; Roland Bingisser; Mikael M Gencay; Peter R Huber; Michael Tamm; Beat Müller Journal: Lancet Date: 2004-02-21 Impact factor: 79.321
Authors: Sabine Mousset; Stella Hermann; Stefan A Klein; Heike Bialleck; Michaele Duchscherer; Barbara Bomke; Barbara Wassmann; Angelika Böhme; Dieter Hoelzer; Hans Martin Journal: Ann Hematol Date: 2005-06-11 Impact factor: 3.673
Authors: R Sabat; C Höflich; W D Döcke; M Oppert; F Kern; B Windrich; C Rosenberger; J Kaden; H D Volk; P Reinke Journal: Intensive Care Med Date: 2001-06 Impact factor: 17.440
Authors: M G Wing; T Moreau; J Greenwood; R M Smith; G Hale; J Isaacs; H Waldmann; P J Lachmann; A Compston Journal: J Clin Invest Date: 1996-12-15 Impact factor: 14.808
Authors: Helena Brodska; Tomas Drabek; Karin Malickova; Antonin Kazda; Antonin Vitek; Tomas Zima; Marketa Markova Journal: Crit Care Date: 2009-03-16 Impact factor: 9.097
Authors: Volker Strenger; Gerald Merth; Herwig Lackner; Stephan W Aberle; Harald H Kessler; Markus G Seidel; Wolfgang Schwinger; Daniela Sperl; Petra Sovinz; Anna Karastaneva; Martin Benesch; Christian Urban Journal: Ann Hematol Date: 2018-02-06 Impact factor: 3.673